View Author
dai: 074095129
scopus: 35323217500

Ploeg, A.T. van der

(Ans van der Ploeg)


patient disease pompe pompe disease muscle study enzyme therapy enzyme replacement therapy treatment glucosidase activity glycogen storage van der ploeg function lysosomal group fatigue children adult replacement month score disorder mps ii erasmus mc university netherland diagnosis result center reuser baseline erasmu syndrome level muscle strength range tissue scoliosi effect table ploeg university blood symptom mutation value infantile-onset pompe disease acid α- glucosidase hearing rotterdam motor alglucosidase alfa number analysis erasmus mc ficiency heart infusion van doorn pa department signi strength late-onset pompe disease mouse mucopolysaccharidosi genetic infant support reuser aj control genet protein weakness enzyme therapy change ventilation assessment alglucosidase




10 Most Recent Publications

Enzyme replacement therapy and fatigue in adults with Pompe disease (Article)
Güngör, D. Vries, J.M. de Plug, I. Ploeg, A.T. van der Brusse, E. Kruijshaar, M.E. Hop, W.C.J. Murawska, M. Berg, L.E.M. van den Reuser, A.J.J. Doorn, P.A. van Hagemans, M.
2013-04-19
Up to five years experience with 11 mucopolysaccharidosis type VI patients (Article)
Brands, M.M.M.G. Oussoren, E. Ruijter, G.J.G. Vollebregt, A.A.M. Hout, H.M.P. van den Joosten, K.F.M. Hop, W.C.J. Plug, I. Ploeg, A.T. van der
2013-03-22
Open-label extension study following the Late-Onset Treatment Study (LOTS) of alglucosidase alfa (Article)
Ploeg, A.T. van der Barohn, R.J. Pestronk, A. Plotkin, H. Rosenbloom, B. Sims, K.B. Tsao, E.C. Carlson, L. Charrow, J. Clemens, P.R. Hopkin, R. Kishnani, P. Laforêt, P. Morgan, C. Nations, S.
2012-11-01
Severely impaired health status at diagnosis of Pompe disease: A cross-sectional analysis to explore the potential utility of neonatal screening (Article)
Rigter, T. Weinreich, S.S. El, C.G. van Vries, J.M. de Gelder, C.M. van Güngör, D. Reuser, A.J.J. Hagemans, M. Cornel, M.C. Ploeg, A.T. van der
2012-11-01
Muscle fiber-type distribution, fiber-type-specific damage, and the Pompe disease phenotype (Article)
Berg, L.E.M. van den Drost, M.R. Schaart, G. Laat, P.C.J. de Doorn, P.A. van Ploeg, A.T. van der Reuser, A.J.J.
2012-10-11
Effect of enzyme therapy and prognostic factors in 69 adults with Pompe disease: An open-label single-center study (Article)
Vries, J.M. de Beek, N.A.M.E. van der Faber, C.G. Verschuuren, J.J. Kruijshaar, M.E. Reuser, A.J.J. Doorn, P.A. van Ploeg, A.T. van der Hop, W.C.J. Karstens, F.P. Wokke, J.H.J. Visser, M. de Engelen, B.G. van Kuks, J.B.M. Kooi, A.J. van der Notermans, N.C.
2012-09-28
Physiotherapy management in late-onset Pompe disease: Clinical practice in 88 patients (Article)
Favejee, M.M. Huisstede, B.M.A. Bussmann, J.B.J. Kruijshaar, M.E. Ploeg, A.T. van der
2012-09-01
First experience with enzyme replacement therapy during pregnancy and lactation in Pompe disease (Article)
Vries, J.M. de Brugma, J.D.C. Özkan, L. Steegers, E.A.P. Reuser, A.J.J. Doorn, P.A. van Ploeg, A.T. van der
2011-12-01
The prevalence and impact of scoliosis in Pompe disease: Lessons learned from the Pompe Registry (Article)
Roberts, M. Kishnani, P.S. Ploeg, A.T. van der Müller-Felber, W. Merlini, L. Prasad, S. Case, L.
2011-12-01
Mucopolysaccharidosis type II: European recommendations for the diagnosis and multidisciplinary management of a rare disease (Article)
Scarpa, M. Almássy, Z. Kamin, W. Kampmann, C. Lampe, C. Lavery, C.A. Leão Teles, E. Link, B. Lund, A.M. Malm, G. Pitz, S. Rothera, M. Beck, M. Stewart, C. Tylki-Szymaska, A. Ploeg, A.T. van der Walker, R. Zeman, J. Wraith, J.E. Bodamer, O.A. Bruce, I.A. Meirleir, L. de Guffon, N. Guillen-Navarro, E. Hensman, P. Jones, S.
2011-11-08